Genelux Corp. (GNLX) AI Stock Analysis

• Market Cap: $306.34M
• Dividend Yield: N/A
• Average Volume (3M): 156.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: -100.00%
• EPS Growth: 7.80%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 37,773,440
• 10 Day Avg. Volume: 178,540
• 30 Day Avg. Volume: 156,945
• PEG Ratio: 0.14
• Price to Book (P/B): 2.82
• Price to Sales (P/S): 9277.96
• P/FCF Ratio: -3.43
• Enterprise Value/Market Cap: 0.27
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -577.90
• Enterprise Value/Ebitda: -2.62
• 1Y Price Target: $22.50
• Price Target Upside: 384.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $4.50 ▼(-3.02% Downside)

Genelux Corp.'s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. The technical analysis suggests bearish momentum, further contributing to the low score. The absence of earnings call insights and corporate events means these factors do not influence the score.

Positive Factors

Equity Improvement

Improved equity position indicates better financial health and potential for future growth, enhancing investor confidence and financial flexibility.

Innovative Cancer Therapies

The focus on innovative cancer therapies positions Genelux as a leader in addressing unmet medical needs, potentially capturing significant market share.

Strategic Partnerships

Strategic partnerships provide revenue streams and enhance product development capabilities, supporting long-term growth and market expansion.

Negative Factors

Negative Profitability

Persistent negative profitability indicates ongoing operational challenges, limiting reinvestment opportunities and affecting long-term sustainability.

High Leverage

High leverage can strain financial flexibility and increase risk, especially in volatile industries, impacting the company's ability to invest in growth.

Negative Cash Flow

Negative cash flow from operations suggests inefficiencies and reliance on external financing, posing risks if funding becomes scarce.

Genelux Corp. Business Overview & Revenue Model

Company Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

How the Company Makes Money

Genelux Corp. generates revenue through several key streams, primarily focused on the development and commercialization of its oncolytic virus therapies. The company earns money by conducting clinical trials and securing partnerships with pharmaceutical companies for co-development and licensing agreements. These collaborations may include upfront payments, milestone payments based on the achievement of specific clinical or regulatory events, and royalties on future sales of successful products. Additionally, Genelux may benefit from government grants and funding aimed at supporting innovative cancer research, which can contribute to its overall financial health. The success of its pipeline products and strategic partnerships play a crucial role in the company's revenue generation.

Genelux Corp. Financial Statement Overview

Summary

Genelux Corp. is facing significant financial challenges, with persistent negative profitability and cash flow issues. Despite some improvements in equity, the company remains highly leveraged. The dependency on financing activities for cash flow sustainability is risky, especially given the volatile nature of the biotechnology industry.

Income Statement

Genelux Corp. shows weak profitability with consistently negative net incomes over the years. The 2024 revenue growth is misleading due to the low base effect from previous years. Gross profit margin is positive due to costs being reported as negative, but net profit margin remains negative, indicating ongoing operational challenges. Both EBIT and EBITDA margins are negative, underscoring significant profitability issues.

Balance Sheet

The company has improved its equity position, transitioning from negative to positive stockholders' equity in recent years, which is a positive sign. However, the debt-to-equity ratio improved but remains concerning, reflecting high leverage. The equity ratio indicates a low percentage of assets financed by equity, limiting financial flexibility.

Cash Flow

Operating cash flows remain negative, indicating ongoing operational losses. Free cash flow is also negative, with no clear growth trajectory. The operating cash flow to net income ratio is not favorable, reflecting inefficiencies in converting income into cash. Financing activities are primarily sustaining the cash position, which poses risks if external financing becomes unavailable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	8.00K	170.00K	11.07M	0.00	0.00
Gross Profit	-143.00K	-895.00K	-848.00K	10.10M	-895.00K	-658.00K
EBITDA	-31.55M	-28.97M	-26.46M	-1.73M	-13.67M	-11.76M
Net Income	-31.87M	-29.87M	-28.30M	-5.21M	-17.80M	-14.86M
Balance Sheet
Total Assets	24.99M	34.72M	27.89M	5.53M	8.13M	14.01M
Cash, Cash Equivalents and Short-Term Investments	20.91M	30.89M	23.19M	397.00K	4.50M	11.35M
Total Debt	1.62M	1.87M	2.52M	26.35M	25.31M	26.06M
Total Liabilities	6.40M	8.44M	8.42M	41.31M	41.24M	36.66M
Stockholders Equity	18.59M	26.27M	19.47M	-35.78M	-33.11M	-22.66M
Cash Flow
Free Cash Flow	-24.13M	-21.61M	-21.30M	-3.62M	-6.58M	-7.22M
Operating Cash Flow	-23.37M	-21.23M	-20.27M	-3.57M	-6.58M	-7.21M
Investing Cash Flow	12.25M	-8.13M	-14.72M	-49.00K	0.00	-20.00K
Financing Cash Flow	9.71M	28.51M	44.02M	-478.00K	-270.00K	18.15M

Genelux Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNLX, the sentiment is Negative. The current price of 4.64 is below the 20-day moving average (MA) of 5.20, below the 50-day MA of 5.70, and above the 200-day MA of 3.83, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 38.04 is Neutral, neither overbought nor oversold. The STOCH value of 15.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNLX.

Genelux Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FATE	51 Neutral	$124.58M	-0.82	-52.35%	―	-46.92%	20.26%
TNXP	49 Neutral	$179.24M	―	-64.99%	―	-8.79%	81.36%
CHRS	47 Neutral	$145.05M	―	―	―	-72.54%	-19972.15%
CRBP	43 Neutral	$128.92M	―	-55.65%	―	―	-17.43%
GNLX	39 Underperform	$306.34M	-9.47	-98.72%	―	-100.00%	7.80%
FBRX	36 Underperform	$135.64M	-1.37	-110.72%	―	―	77.08%

Genelux Corp. Corporate Events

Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment

The OnPrime study, officially titled ‘A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician’s Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)’, aims to evaluate the safety and efficacy of Olvi-Vec followed by chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. This study is significant as it builds on promising Phase II results, potentially offering a new treatment avenue for this challenging condition.

Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment

Genelux Corp. is currently conducting a Phase 2 clinical study titled A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance. The study aims to evaluate the efficacy and safety of Olvimulogene Nanivacirepvec (Olvi-Vec), an oncolytic vaccinia virus, in combination with chemotherapy and immune checkpoint inhibitors for advanced non-small-cell lung cancer (NSCLC) patients.

Genelux Corp. Lowers Stock Option Exercise Prices

On September 1, 2025, Genelux Corporation’s Board of Directors approved a reduction in the exercise prices of certain outstanding stock options under its 2022, 2019, and 2009 Equity Incentive Plans, lowering them to $3.33 per share. This strategic move aims to retain and incentivize employees while preserving cash resources, without causing stock dilution. Additionally, on August 27, 2025, the company held its Annual Meeting of Stockholders, where key decisions included the election of Class III Directors and the ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (GNLX) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.